Shedding light on dry eye: new study tests IPL and LED mask therapies
NCT ID NCT06004895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how two light-based treatments—intense pulsed light (IPL) and low-level light therapy (LLLT)—work for dry eye disease caused by clogged oil glands. Twenty-six participants received four treatment sessions, with one eye getting IPL plus LLLT and the other getting a sham IPL plus LLLT. The goal was to measure changes in tear stability and dry eye symptoms over three months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Intense pulsed light (IPL) and low-level light therapy (LLLT) devices
- What this could lead to
- If successful, this could help explain how light-based treatments relieve dry eye symptoms and improve oil gland function, leading to better targeted therapies.
- What could go wrong
- This is a small, completed study (26 people) focused on understanding how the treatments work, not on proving they are effective. Results may not apply to everyone with dry eye.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
26 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individuals with dry eye disease symptoms (Ocular Surface Disease Index questionnaire (OSDI) score ≥ 13 or Dry Eye Questionnaire (DEQ5) score \> 6) and signs (tear film instability measured with non-invasive tear break-up time \< 10 s or ocular surface damage measured using special dyes placed on the front surface of the eyes that temporarily stains any aggravated or damaged cells: \> 5 corneal spots, \> 9 conjunctival spots or lid margin staining ≥ 2mm in length and ≥ 25% in width) (Wolffsohn et al., 2017) * Individuals need to also have Meibomian gland dysfunction. The diagnosis of Meibomian gland dysfunction depends on how many of 5 glands in the central lower eyelid can express oil, and the quality of the oil. A diagnosis is made if there is decreased expressibility (grade 1-3 on the Pflugfelder scale) and reduced quality of oil (grade 1-3 on Bron scale). Any presence of gland blockage and/or loss of oil glands grade 2 to grade 4 of either eyelid \[Pult and Reide-Pult, 2013\]) will also justify a diagnosis of Meibomian gland dysfunction * Age ≥ 18 years, male or female * Able to provide written consent in English * Able to attend multiple visits (4 treatment visits) and followed up for 2 weeks and 3 months after final treatment Exclusion Criteria: * Pregnancy * Contraindications to IPL treatment (Individuals with darker skin types - Fitzpatrick skin type V or VI, photosensitive epilepsy, tattoos, implants, electrical or acoustic prosthetics, semi-permanent make-up, pigmented lesions or skin cancer in the treatment area, pacemakers, use of photosensitising medication the past 3 months or during treatment period) * Facial or ocular IPL or LLLT treatment within the past 6 months or during study period in addition to those provided in the study * Use of topical medical eyedrops in the past 3 months or during study period * Contact lens wear in the past 2 weeks or during study period * Systemic conditions that can cause dry eye disease or corneal nerve loss including diabetes and Sjögren's syndrome * Other active ocular surface diseases or history of ocular surgery or corneal infections * Individuals with 1 eye
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dry eye syndromes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aston Dry Eye Clinic
Birmingham, West Midlands, B4 7ET, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye scans as a window to the body: study probes retinal imaging across diseases
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Can a thymosin beta 4 eye drop soothe dry eye?
- Could your own blood cure dry eye? plasma drops put to the test
- New eye drops could bring relief to millions with chronic dry eye
- Eye rinse device aims to soothe dry eye pain